Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | TPH1 | P17752 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379268 | 1.00 | FFAR1 (0.56) | FFAR1PPARGPPARAACACBALPI | |
| SCHEMBL1768559 | 0.88 | SLC7A5 (0.70) | FFAR1PPARGPPARAALPIPKM | |
| SCHEMBL29584001 | 0.88 | SLC7A5 (0.70) | FFAR1PPARGPPARAALPIPKM | |
| SCHEMBL12379284 | 0.88 | SLC7A5 (0.70) | FFAR1PPARGPPARAALPIPKM | |
| SCHEMBL515521 | 0.88 | SLC7A5 (0.70) | FFAR1PPARGPPARAALPIPKM | |
| Hydrochloric Acid SCHEMBL16816023 | 0.87 | SLC7A5 (0.68) | FFAR1PPARGPPARAALPIPKM | |
| Hydrochloric Acid SCHEMBL2292782 | 0.87 | SLC7A5 (0.68) | FFAR1PPARGPPARAALPIPKM | |
| SCHEMBL14618135 | 0.87 | SLC7A5 (0.59) | SLC7A5LTA4H | |
| Hydrochloric Acid SCHEMBL16816020 | 0.87 | SLC7A5 (0.68) | FFAR1PPARGPPARAALPIPKM | |
| SCHEMBL8255298 | 0.86 | ACACB (0.53) | FFAR1PPARGPPARAACACBALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | FFAR1 2285/4885PPARG 1936/4885PPARA 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.